Aarti Pharmalabs Q1 FY27 results: ₹149 Cr capex

Board meeting outcome and key decisions

Aarti Pharmalabs Limited said its Board of Directors met on August 7, 2026, and approved a set of financial and strategic decisions. The board cleared the unaudited financial results for the quarter ended June 30, 2026, on both standalone and consolidated bases. The results were accompanied by a Limited Review Report placed before the Audit Committee.

Alongside the quarterly numbers, the board approved a capacity addition for the development of an intermediate manufacturing block. The company put the estimated capital expenditure for this project at ₹149 crore. It also approved leadership changes that will take effect from October 1, 2026.

Unaudited Q1 FY27 results approved

The company’s unaudited results relate to the first quarter of FY27, which ended on June 30, 2026. Aarti Pharmalabs reported consolidated operational revenue of ₹536 crore for the quarter. Consolidated net profit for the quarter was reported at ₹76.14 crore.

On the standalone side, the company disclosed profit after tax (PAT) of ₹7,130.66 lakh for the quarter, which equals ₹71.31 crore. Total comprehensive income for the quarter on a standalone basis was ₹7,312.80 lakh, or ₹73.13 crore.

Consolidated performance: revenue and profit growth

Aarti Pharmalabs reported that consolidated operational revenue rose to ₹536 crore from ₹386 crore in the same period last year. The company also reported a year-on-year rise in consolidated net profit to ₹76.14 crore, from ₹46.0 crore in Q1 FY26.

The press release data also described consolidated revenue at 5.36 billion rupees and consolidated PAT at 0.76 billion rupees, which align with ₹536 crore and ₹76 crore when expressed in crore. The company stated consolidated revenue rose 38.7% year on year, and consolidated PAT rose 65.3% year on year.

Standalone performance: revenue and PAT trends

On a standalone basis, Aarti Pharmalabs reported revenue of 5.35 billion rupees, or about ₹535 crore, and PAT of 0.71 billion rupees, or about ₹71 crore, for the quarter. The press release noted standalone revenue rose 42.5% year on year and standalone PAT rose 49.4% year on year.

Separately, the standalone PAT number in the unaudited results was disclosed as ₹71.31 crore for Q1 FY27. The company also reported that standalone net profit for the quarter was ₹71.31 crore compared with ₹62.03 crore in the previous quarter.

₹149 crore capex cleared for intermediate block

A key strategic item from the board meeting was the approval of a capacity addition through the development of an intermediate block. The company estimated the capex for this expansion at ₹149 crore. It said the facility is intended to serve intermediate and CDMO customers.

Aarti Pharmalabs estimated the period for this capacity addition at about one year. The company said funding for the project will come through a mix of internal accruals and borrowings.

Why the intermediate block matters for operations

The intermediate block expansion is positioned around supplying intermediates and CDMO customer demand. While the company has not provided customer names or product-level details in the update, it has tied the project explicitly to intermediate and contract development and manufacturing (CDMO) requirements.

For investors, this kind of capex decision typically signals an intent to add manufacturing capability and support future volumes. In this case, the company has also specified the expected build timeline and the proposed financing mix, which provides clearer visibility on execution planning.

Leadership changes effective October 1, 2026

The board also approved changes in senior leadership roles effective October 1, 2026. Aarti Pharmalabs said Rashesh C. Gogri will take over as Managing Director from that date. Hetal Gogri Gala will transition to the role of Executive Director from the same effective date.

The company presented these changes as part of a broader leadership restructuring to streamline business focus beginning October 1, 2026.

Upcoming Q1 earnings call

Aarti Pharmalabs also scheduled its Q1 FY27 earnings conference call for August 10, 2026. The company said the call will be used to discuss the financial performance for the quarter ended June 30, 2026.

For market participants, the call is expected to be the next formal forum where management can provide additional colour on quarterly performance and the approved capacity addition, within the boundaries of what the company discloses.

Key numbers at a glance

All figures are presented in ₹ crore for consistency.

Timeline of disclosed events

Market impact and what to track next

The update combines three market-relevant inputs: Q1 FY27 profitability, a clearly sized capex decision, and a dated leadership transition. The revenue and profit figures provide a quarterly performance snapshot, while the ₹149 crore capex adds a concrete investment plan with an estimated one-year implementation timeline. The leadership change provides a defined date for management role transitions, which investors often track for continuity and accountability.

The next immediate event on the calendar is the August 10, 2026 earnings call. Separately, execution progress on the intermediate block, including commissioning timelines and any follow-on disclosures on utilisation or customer mix, will be key updates to watch based on what the company has already announced.

Conclusion

Aarti Pharmalabs’ August 7, 2026 board meeting resulted in approval of unaudited Q1 FY27 results, a ₹149 crore intermediate block capacity addition planned over about a year, and leadership changes effective October 1, 2026. The company is set to discuss the quarter’s performance in its earnings call scheduled for August 10, 2026.